Who is sponsoring NCT05505747?

NCT05505747 is sponsored by Austin V Stone.

What condition does NCT05505747 study?

NCT05505747 studies Meniscus Tear, Meniscus; Derangement, Meniscus Lesion, Meniscus Disorder.

What drugs are being tested in NCT05505747?

Interventions: Fisetin, Placebo oral capsule.

What is the status of NCT05505747?

NCT05505747 is currently WITHDRAWN.

Last reviewed 2025-05-05 · How we verify

Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair

NCT05505747 Phase 2/Phase 3 WITHDRAWN

Arthroscopic meniscal procedures are the most commonly performed orthopaedic procedure in the U.S. affecting 15% of Americans ages 10-65 years. Meniscus injury is also known to increase the risk of posttraumatic osteoarthritis (PTOA). The current randomized clinical trial will test a novel intervention after meniscal repair that combines an oral senolytic fisetin and real-time biofeedback program to restore joint loading and subsequent return to activity.

Details

Lead sponsor	Austin V Stone
Phase	Phase 2/Phase 3
Status	WITHDRAWN
Start date	2025-07
Completion	2026-02

Conditions

Meniscus Tear
Meniscus; Derangement
Meniscus Lesion
Meniscus Disorder

Interventions

Fisetin
Placebo oral capsule

Primary outcomes

Change in International Knee Documentation Committee (IKDC) Score between baseline and 1 year — Baseline, 1 year
The IKDC Score was designed to assess patients with a variety of knee disorders including meniscal injuries. The IKDC consists of 18 items, and scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

Countries

United States